Logo of EchoIQ (ASX:EIQ)Latest EchoIQ (ASX:EIQ) News

Page 1
Page 1 of 4

Echo IQ’s EchoSolv assessments surge as FDA appeal and US expansion enter decisive phase

Echo IQ’s FDA-cleared EchoSolv AS platform processed 9,697 full-result assessments in the September quarter, while the company ended the period with A$107.8 million in cash. The stronger balance sheet gives it room to pursue US enterprise deployments, but commercial conversion and the unresolved EchoSolv HF regulatory pathway remain the key tests.
Victor Sage
26 Oct 2026

Echo IQ wins FDA appeal review after EchoSolv HF clearance setback

Echo IQ has secured an FDA supervisory review of the regulator’s Not Substantially Equivalent decision for EchoSolv HF. The review creates a formal route for reconsideration, but does not change the current regulatory determination or guarantee clearance.
Victor Sage
12 Oct 2026

Market Wrap - Week 38 (14 Sept -> 18 Sept) 2026

Small-cap resources led the week, while takeover offers and defence contracts added support across the market.
Investors still had to weigh approvals, cash needs and project delivery against strong headline results.
Logan Eniac
19 Sept 2026

Echo IQ maps three FDA routes after EchoSolv HF setback

Echo IQ says it sees a path to US FDA clearance for EchoSolv HF after receiving a Not Substantially Equivalent determination. The company is weighing an appeal, an Ombudsman review or a fresh 510(k) submission, but has not selected a route or set a firm timetable.
Victor Sage
17 Sept 2026

Market Wrap - Week 31 (27 July -> 31 July) 2026

Small-cap shares produced the week’s biggest moves, led by Xenitra’s 60% surge and Carnaby Resources’ takeover jump.
Mining news dominated, but sharp falls in Lotus Resources and several funded developers showed that new capital can still unsettle investors.
Logan Eniac
1 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Echo IQ Secures $20m Pro Medicus Deal and Raises $110m to Boost US AI Cardiovascular Push

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.
Ada Torres
27 July 2026

Market Wrap - Week 27 (29 June -> 3 July) 2026

A tiny gold explorer, a battery materials stock and a biotech name led a week packed with dealmaking, drilling news and fresh funding. Resources did most of the heavy lifting, while several big gaps either held firm or gave back part of their early jump.
Logan Eniac
4 July 2026

Healthcare Wrap - Week 27 (29 June -> 3 July) 2026

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.
Logan Eniac
4 July 2026

Echo IQ Secures Exclusive Access to Up to 1 Million Echocardiography Studies

Echo IQ has locked in a pivotal exclusive data licensing deal with Advara HeartCare, gaining access to as many as one million de-identified echocardiography studies, a move set to turbocharge its cardiovascular AI development.
Ada Torres
2 July 2026

Echo IQ Secures A$110 Million to Accelerate US Expansion and AI Cardiovascular Innovation

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.
Ada Torres
1 July 2026

Market Wrap - Week 26 (22 June -> 26 June) 2026

Big moves came from small and mid-cap names tied to drilling, project studies and fresh funding. Healthcare, mining and takeover stocks all had a busy week, but not every strong announcement held its gains.
Logan Eniac
27 June 2026